To study role of Homocysteine as a biochemical marker in various obstetrical complications

Pushpraj Singh Baghel; Ajay Kumar Mishra

doi:10.53730/ijhs.v6nS1.4772

Authors

Pushpraj Singh Baghel Associate Professor, Department of Pathology, NSCB Medical College Jabalpur, Madhya Pradesh, India
Ajay Kumar Mishra
ajay.maju@gmail.com
Associate Professor, Department of Physiology, NSCB Medical College Jabalpur, Madhya Pradesh, India

Keywords:

abruptio placentae, eclampsia, hyperhomocystenemia, IUGR, NTD

Abstract

Low plasma homocysteine level during an uncomplicated pregnancy was first demonstrated by Kang et al almost 20 years ago, & this has subsequently been confirmed by numerous investigators. Plasma homocysteine concentrations are 30-60% lower in pregnant women than in non-pregnant women & the lowest levels are observed in the second trimester. Hyperhomocysteinaemia is associated with adverse pregnancy outcome, such as spontaneous early abortion, placental vasculopathy and birth defects. It is not only neural tube defects (NTDs) but also cardiac malformations and cleft lip and/or palate etc. Objective of study is to observe role of Homocysteine as a biochemical marker in various obstetrical complications and to evaluate Homocysteine as a risk factor in obstetrical complications. ADVIA- Centaur equipment is used and method is Chemiluminescence. It has been found that Pre-eclampsia cases have got higher Probabilities of having raised Homocysteine as compared to non-Pre-eclamptic cases, on the other hand Recurrent abortions has been found to be associated with high Homocysteine, indicating adverse effect of Hyperhomocystenemia.

Downloads

Download data is not yet available.

References

American Heart Association. (1999). AHA Science Advisory. Homocysteine, diet and cardiovascular diseases. Circulation, 99, 178-82.

Boers, G. H. (1994). Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. The Netherlands journal of medicine, 45(1), 34-41.

Chait, A., Malinow, M. R., Nevin, D. N., Morris, C. D., Eastgard, R. L., Kris-Etherton, P., ... & McCarron, D. A. (1999). Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease. The American journal of clinical nutrition, 70(5), 881-887.

Graham, I. M., Daly, L. E., Refsum, H. M., Robinson, K., Brattström, L. E., Ueland, P. M., ... & Andria, G. (1997). Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. Jama, 277(22), 1775-1781.

Holford, P. (2009). The Optimum Nutrition Bible: The Book You Have To Read If Your Care About Your Health. Hachette UK.

Jacques, P. F., Bostom, A. G., Wilson, P. W., Rich, S., Rosenberg, I. H., & Selhub, J. (2001). Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. The American journal of clinical nutrition, 73(3), 613-621.

Kalhan, S. C., & Iben, S. (2000). PROTEIN METABOLISM IN THE EXTREMELY LOW–BIRTH WEIGHT INFANT. Clinics in perinatology, 27(1), 23-56.

Miner, S. E., Evrovski, J., & Cole, D. E. (1997). Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clinical biochemistry, 30(3), 189-201.

Mosharov, E., Cranford, M. R., & Banerjee, R. (2000). The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry, 39(42), 13005-13011.

Mudd, S. H., Finkelstein, J. D., Irreverre, F., & Laster, L. (1964). Homocystinuria: an enzymatic defect. Science, 143(3613), 1443-1445.

Neki, N. S., & Arora, P. (2001). A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension. Journal of the Indian Medical Association, 99(11), 640-641.

Prasad, K. (1999). Homocysteine, a risk factor for cardiovascular disease. International Journal of angiology, 8(01), 76-86.

Puri, A., Gupta, O. K., Dwivedi, R. N., Bharadwaj, R. P., Narain, V. S., & Singh, S. (2003). Homocysteine and lipid levels in young patients with coronary artery disease. J Assoc Physicians India, 51, 681-5.

Selhub, J. (1999). Homocysteine metabolism. Annual review of nutrition, 19(1), 217-246.

Stampfer, M. J., & Malinow, M. R. (1995). Can lowering homocysteine levels reduce cardiovascular risk?. New England Journal of Medicine, 332(5), 328-329.

Steegers?Theunissen, R. P., Wathen, N. C., Eskes, T. K., van Raaij?Selten, B., & Chard, T. (1997). Maternal and fetal levels of methionine and homocysteine in early human pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology, 104(1), 20-24.

Ubbink, J. B., Vermaak, W. H., van der Merwe, A., Becker, P. J., Delport, R., & Potgieter, H. C. (1994). Vitamin requirements for the treatment of hyperhomocysteinemia in humans. The Journal of nutrition, 124(10), 1927-1933.

Wald, D. S., Law, M., & Morris, J. K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj, 325(7374), 1202.